Argenx has been granted a patent for binding molecules that inhibit IL-6 activity, useful in treating inflammatory diseases and cancer. The method involves administering specific antibodies or fragments to neutralize IL-6, as detailed in the claim. GlobalData’s report on Argenx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Argenx SE - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Argenx, Personalized cancer vaccines was a key innovation area identified from patents. Argenx's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Neutralizing il-6 activity using specific antibodies

Source: United States Patent and Trademark Office (USPTO). Credit: Argenx SE

A recently granted patent (Publication Number: US11827701B2) discloses a method for neutralizing IL-6 activity in individuals requiring treatment. The method involves administering an effective amount of an antibody or antigen binding fragment that specifically binds to IL-6. The antibody comprises specific amino acid sequences in the VH and VL domains, as detailed in the patent claims.

The method outlined in the patent is particularly relevant for individuals with inflammatory diseases such as rheumatoid arthritis, cancer-related conditions like prostate cancer, and other ailments where IL-6 activity plays a significant role. The antibody or antigen binding fragment described in the patent includes specific mutations in the human Fc domain, enhancing its efficacy in neutralizing IL-6 activity. By targeting IL-6, which is known for promoting cell proliferation and binding to IL-6 receptors, this method offers a promising approach for managing various health conditions effectively.

To know more about GlobalData’s detailed insights on Argenx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies